Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 89,83 € (-3,54%). La mediana è 91,57 € (-1,68%).
| Acquista |
18 |
| Mantieni |
8 |
| Vendi |
1 |
Notizie Vai al feed delle notizie
Halozyme presents tiered licensing growth strategy and strong Q2 results
At the Morgan Stanley Healthcare Conference, Halozyme highlighted record revenue of $308 million for Q2 2024 and accelerated growth in partner products. The company emphasized the diversification of its technologies (ENHANZE, Hypercon, Surf Bio), five new business partnerships in 2024, and optimistic revenue guidance for 2024 as well as long‑term targets through 2028. Management views political risks and tariffs as having little impact, expects further contract signings, and is relying on AI‑driven efficiency, buybacks and selective M&A to strengthen the licensing base. » Altro su de.investing.com
Halozyme sees growth from subcutaneous delivery
Halozyme reported strong growth at the Wells Fargo Healthcare Conference: revenue in Q2 2024 rose to $481m (+48%) and licensing income exceeded $300m (+50%). The ENHANZE platform is driving commercial switches to subcutaneous formats, and the company is expanding its pipeline with HyperCon, autoinjector technologies and several new partnerships. Management cites patent protection issues, a pending lawsuit with Merck and potential future declines in license royalties as risks, but emphasizes strong free cash flow, room for investment, share buybacks and debt reduction. » Altro su de.investing.com
Halozyme Therapeutics hits new all-time high at $109.69
Halozyme Therapeutics' stock rose to a record high of $109.69, bringing market capitalization to about $12.4 billion. The shares are up 46.06% over the past 12 months, 54% over the past six months and 60% year-to-date. In the second quarter Halozyme beat expectations with a non-GAAP EPS of $2.28 (expectation $1.81) and revenue of $481 million (expectation $401.27 million), driven by record licensing revenues, after which the full-year guidance was raised. Analysts reacted positively: Citizens slightly raised its price target to $93 with a "market outperform" rating, and H.C. Wainwright reaffirmed "buy" with a $115 target following positive partner data. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | |
|---|---|---|
| Ricavi | 421,46 Mln | 52,51% |
| Utile lordo | 352,09 Mln | 58,64% |
| Utile netto | 201,45 Mln | 43,77% |
| EBITDA | 280,39 Mln | 43,82% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 11,09 Mld € |
Numero di azioni | 118,61 Mln |
Massimo/minimo a 52 settimane | 96,93 € - 53,40 € |
| Dividendi | No |
Beta | 0,88 |
Rapporto P/E | 30,45 |
Rapporto PEG | -1,42 |
Rapporto P/B | 87,58 |
Rapporto P/S | 7,64 |
Profilo aziendale
Halozyme Therapeutics, Inc. ist als biopharmazeutisches Technologieplattformunternehmen in den Vereinigten Staaten, der Schweiz, Irland, Belgien, Japan und international tätig. Die Produkte des Unternehmens basieren auf der ENHANZE-Arzneimittelverabreichungstechnologie, einem patentierten rekombinanten menschlichen Hyaluronidase-Enzym (rHuPH20), das die subkutane Verabreichung von injizierbaren Biologika wie monoklonalen Antikörpern und anderen therapeutischen Molekülen sowie kleinen Molekülen und Flüssigkeiten ermöglicht. Das Hauptprodukt des Unternehmens ist Hylenex rekombinant, eine Formulierung von rHuPH20 zur Erleichterung der subkutanen Flüssigkeitsverabreichung, um die Dispersion und Absorption anderer injizierter Medikamente bei der subkutanen Urographie zu verbessern und die Resorption von Röntgenkontrastmitteln zu erhöhen. Das Unternehmen entwickelt auch Perjeta, RITUXAN HYCELA und MabThera SC für die Behandlung von Non-Hodgkin-Lymphomen und chronischer lymphatischer Leukämie (CLL), RITUXAN SC für Patienten mit CLL und HYQVIA für die Behandlung von Immunschwächekrankheiten. Darüber hinaus entwickelt das Unternehmen Tecentriq zur Behandlung von nicht-kleinzelligem Lungenkrebs, OCREVUS zur Behandlung von Multipler Sklerose, DARZALEX zur Behandlung von Patienten mit Amyloidose, schwelendem Myelom und Multiplem Myelom, Nivolumab zur Behandlung von soliden Tumoren, ARGX-113, einen menschlichen neonatalen Fc-Rezeptor, ARGX-117 zur Behandlung von Autoimmunerkrankungen und BMS-986179, einen Anti-CD-73-Antikörper. Das Unternehmen kooperiert mit F. Hoffmann-La Roche, Ltd; Hoffmann-La Roche, Inc; Baxalta US Inc; Baxalta GmbH; Pfizer Inc; Janssen Biotech, Inc; AbbVie, Inc.Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; und ViiV Healthcare Limited für kleine und große Molekül-Targets zur Behandlung und Prävention von HIV. Halozyme Therapeutics, Inc. wurde 1998 gegründet und hat seinen Sitz in San Diego, Kalifornien.
| Nome | Halozyme Therapeutics |
| CEO | Helen I. Torley |
| Sede centrale | San Diego,
ca Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 03/10/2008 |
| Dipendenti | 423 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | HALO |
London Stock Exchange | 0J2O.L |
Frankfurt | RV7.F |
Düsseldorf | RV7.DU |
London | 0J2O.L |
SIX | RV7.SW |
München | RV7.MU |
